Yeasts encoding tumour antigens in cancer immunotherapy

被引：49

作者：

Franzusoff, A ^{[1
]}

Duke, PC ^{[1
]}

King, TH ^{[1
]}

Lu, YN ^{[1
]}

Rodell, TC ^{[1
]}

机构：

[1] Globelmmune Inc, Aurora, CO 80010 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2005年 / 5卷 / 04期

关键词：

animal models; cancer immunotherapy; tumour; vaccine; whole recombinant yeast;

D O I：

10.1517/14712598.5.4.565

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immunotherapy for cancer represents an attractive therapeutic target because of its specificity and lack of toxicity, but products investigated so far have been limited by neutralisation, complexity of manufacturing and requirement for patient-specific products. Recombinant yeast cells are capable of stimulating the immune system to produce highly specific and potent cellular responses against target protein antigens with little toxicity. Data from animal models suggest that Tarmogens (TM) (yeast-based immunotherapeutics) can elicit protective immunity against xenografted and chemically induced tumours. This concept is now being tested in a Phase I trial in patients with colorectal, pancreatic and non-small cell lung cancers.

引用

页码：565 / 575

页数：11

共 47 条

[1]

Abrams SI, 1996, SEMIN ONCOL, V23, P118

[2] Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations [J].